Log in

NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News

$11.70
+0.10 (+0.86 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.30
Now: $11.70
$11.88
50-Day Range
$9.95
MA: $10.86
$11.82
52-Week Range
$5.61
Now: $11.70
$23.23
Volume34,600 shs
Average Volume93,407 shs
Market Capitalization$208.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.48
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
Kalvista Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.13 million
Book Value$5.61 per share

Profitability

Net Income$-20,820,000.00
Net Margins-263.38%

Miscellaneous

Employees33
Market Cap$208.85 million
Next Earnings Date7/20/2020 (Estimated)
OptionableNot Optionable

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has Kalvista Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 32.1% and is now trading at $11.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kalvista Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, July 20th 2020. View our earnings forecast for Kalvista Pharmaceuticals.

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its quarterly earnings results on Tuesday, March, 10th. The specialty pharmaceutical company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.26. The specialty pharmaceutical company had revenue of $1.58 million for the quarter, compared to analyst estimates of $3.30 million. Kalvista Pharmaceuticals had a negative return on equity of 32.17% and a negative net margin of 263.38%. View Kalvista Pharmaceuticals' earnings history.

What price target have analysts set for KALV?

3 Wall Street analysts have issued 12 month price targets for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $31.00. On average, they expect Kalvista Pharmaceuticals' stock price to reach $29.67 in the next year. This suggests a possible upside of 153.6% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals.

Has Kalvista Pharmaceuticals been receiving favorable news coverage?

Headlines about KALV stock have trended neutral recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutKalvista Pharmaceuticals.

Are investors shorting Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 359,200 shares, a drop of 10.6% from the April 15th total of 401,600 shares. Based on an average daily trading volume, of 140,400 shares, the short-interest ratio is presently 2.6 days. Approximately 2.9% of the company's stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Who are Kalvista Pharmaceuticals' major shareholders?

Kalvista Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (8.27%), Ikarian Capital LLC (5.30%), BlackRock Inc. (4.89%), Pictet Asset Management Ltd. (3.54%), Orbimed Advisors LLC (2.36%) and Ghost Tree Capital LLC (1.96%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View institutional ownership trends for Kalvista Pharmaceuticals.

Which major investors are selling Kalvista Pharmaceuticals stock?

KALV stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, International Biotechnology Trust PLC, Franklin Resources Inc., Squarepoint Ops LLC, WINTON GROUP Ltd, Wellington Management Group LLP, UBS Group AG, and Victory Capital Management Inc.. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Christopher Yea, Edward P Feener, and Thomas Andrew Crockett. View insider buying and selling activity for Kalvista Pharmaceuticals.

Which major investors are buying Kalvista Pharmaceuticals stock?

KALV stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Orbimed Advisors LLC, DAFNA Capital Management LLC, Janus Henderson Group PLC, Sphera Funds Management LTD., JPMorgan Chase & Co., and Geode Capital Management LLC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland. View insider buying and selling activity for Kalvista Pharmaceuticals.

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $11.70.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $208.85 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.